Humacyte Inc.

HUMA | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.59

$0 (0.00%)

Sep 22, 2026, 2:33 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

Rating

Updated: Sep 8, 2026

23.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $98.88M

1D Range

0.58 0.61

52W Range

0.53 2.55

Valuation (TTM)

PE -1.16

PB 3.17

EV/EBITDA -1.07

Valuation (NTM)

Forward PE N/A

Forward PEG 0.03

Price Target $2

Cash Flow

FCF Yield -98.4%

SBC Adj. FCF Yield -109.2%

SBC Impact -11.0%

Margins

Gross Margin -666.8%

Operating Margin -5240.8%

FCF Margin -4599.7%

Growth (CAGR)

Revenue 3Y | 5Y 309.0% | 2.4%

Dil EPS 3Y | 5Y 50.7% | -1.7%

FCF 3Y | 5Y -8.2% | -5.2%

Returns

ROA -70.0%

ROE -938.2%

ROIC -89.2%

Financial Health

Net Cash

$43.58M

Current Ratio 6.21

Interest Coverage -10.80

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array o...

Sector Healthcare

Industry Biotechnology

Employees 184

IPO Date Nov 30, 2020

Website www.humacyte.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+238.98%

Buy (5)

Hold (1)

Sell (0)

Analyst Details ➞